Research Article
Kidney-Related Outcome in Cardiorenal Syndrome Type 3
Table 1
Baseline characteristics of all patients included.
| Variable | Baseline characteristics |
| Gender (females/males) | 42 (44.2%)/53 (55.8%) | Age (mean years+/−SD) | 79.6+/−10.5 | In-hospital stay (mean days+/−SD) | 21.1+/−17.3 | AKIN stage (1/2/3) | 19 (20%)/38 (40%)/38 (40%) | Initial serum creatinine (micro-Mol/L+/−SD) | 231+/−163 | Peak serum creatinine (micro-Mol/L+/−SD) | 347.4+/−157.2 | Serum creatinine before discharge (micro-Mol/L+/−SD) | 218.8+/−141.4 | Initial serum sodium (mMol/L+/−SD) | 137.6+/−6.2 | Minimal serum sodium (mMol/L+/−SD) | 135.1+/−6 | Peak serum sodium (mMol/L+/−SD | 144.1+/−5.5 | Initial serum potassium (mMol/L+/−SD) | 4.9+/−0.9 | Minimal serum potassium (mMol/L+/−SD) | 3.7+/−0.7 | Peak serum potassium (mMol/L+/−SD) | 5.2+/−0.8 | Initial NT-proBNP (pg/mL) | 10,562+/−10,395 | Peak NT-proBNP (pg/mL) | 12,298+/−11,505 | Initial CRP (mg/L+/−SD) | 51.4+/−66.4 | Peak CRP (mg/L+/−SD) | 134.1+/−105.5 | Vasopressors (n and %) | 8 (8.4%) | Invasive ventilation (n and %) | 12 (12.6%) | Arterial hypertension (n and %) | 87 (91.6%) | Diabetes (n and %) | 54 (56.8%) | Obesity (n and %) | 52 (55.3%) | Preexisting CHF (n and %) | 26 (27.4%) | Preexisting CAD (n and %) | 39 (41.1%) | COPD (n and %) | 18 (18.9%) | Hyperuricemia (n and %) | 23 (24.2%) | History of cancer (n and %) | 26 (27.4%) | Nephrotoxic drugs (n and %) | NSAIDs | 33 (34.7%) | Vancomycin | 2 (2.1%) | Aminoglykosides | 0 | Amphotericin B | 0 | Other | 4 (4.2%) |
|
|